Androgens and poor responders: are we ready to take the plunge into clinical therapy?

ObjectiveTo review and summarize data from the scientific literature on the use of androgens to improve ovarian function.DesignReview of pertinent literature.SettingUniversity hospital.Patient(s)Women exposed to androgens.Intervention(s)None.Main Outcome Measure(s)Critical review of the literature.Result(s)The artificial increase of intra-ovarian androgen concentrations constitutes an attractive concept for improving the deficient ovarian function of poor responders. Data from studies conducted in animals treated with high-dose androgens, together with observations made in hyperandrogenic women or female-to-male transsexuals receiving virilizing androgen doses, indicate that androgens may increase follicle responsiveness to FSH and/or the number of growing follicles in the ovary. Yet, definite clinical demonstration of such a concept still is not available.Conclusion(s)Current clinical approaches aiming at increasing androgen availability in the ovary showed conflicting results. Therefore, additional studies using proper strategies to achieving higher intra-ovarian androgen concentrations for longer intervals are required to define the clinical efficiency of androgens in poor responders.